MAUNA KEA TECHNOLOGIES |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.39 EUR | +2.77% |
|
0.00% | -17.20% |
| Apr. 25 | Mauna Kea Technologies SA Provides Sales Guidance for the Year 2024 | CI |
| Apr. 03 | Mauna Kea: first Italian center for Cellvizio | CF |
| Sales 2023 * | 6.2M 6.63M | Sales 2024 * | 7.1M 7.59M | Capitalization | 24M 25.66M |
|---|---|---|---|---|---|
| Net income 2023 * | 10M 10.69M | Net income 2024 * | -7M -7.48M | EV / Sales 2023 * | 6.39 x |
| Net Debt 2023 * | 15.6M 16.68M | Net Debt 2024 * | 22.8M 24.38M | EV / Sales 2024 * | 6.59 x |
| P/E ratio 2023 * |
1.63
x | P/E ratio 2024 * |
-2.44
x | Employees | 67 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 76.84% |
More Fundamentals
* Assessed data
More news
Latest transcript on Mauna Kea Technologies
More press releases
More news
| 1 day | +2.77% | ||
| Current month | -8.88% | ||
| 1 month | +8.03% | ||
| 3 months | -18.92% | ||
| 6 months | -22.00% | ||
| Current year | -17.20% |
1 week
0.38
0.41
1 month
0.380.46
Current year
0.340.52
1 year
0.340.77
3 years
0.341.48
5 years
0.342.37
10 years
0.3412.10
| Managers | Title | Age | Since |
|---|---|---|---|
Sacha Loiseau
CEO | Chief Executive Officer | - | 00-04-30 |
| Director of Finance/CFO | - | 23-06-12 | |
Nathalie Lecoq
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chris McFadden
BRD | Director/Board Member | - | 07-12-31 |
Sacha Loiseau
CEO | Chief Executive Officer | - | 00-04-30 |
Molly O'Neill
BRD | Director/Board Member | 60 | 18-01-14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.39 | +2.77% | 520,239 |
| 24-04-25 | 0.3795 | 0.00% | 85,330 |
| 24-04-24 | 0.3795 | +0.40% | 41,126 |
| 24-04-23 | 0.378 | -2.58% | 113,831 |
| 24-04-22 | 0.388 | -0.51% | 72,587 |
Real-time Euronext Paris, April 26, 2024 at 11:35 am EDT
More quotes
Mauna Kea Technologies specializes in designing, developing, and selling optical biopsy devices and tools. The group's products are intended for visualizing and detecting cellular abnormalities during the gastrointestinal and pulmonary endoscopic procedures, primarily in cancer patients. Net sales break down by activity as follows:
- sales of accessories (41.9%): mini-probes, software, etc.;
- sales of system (39.8%);
- services (18.3%).
Net sales are distributed geographically as follows: the United States and Canada (56.2%), Asia/Pacific (5.4%), Europe-Middle East-Africa and other (38.4%).
Calendar
2024-06-05
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.39
EUR
Average target price
1.955
EUR
Spread / Average Target
+401.28%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.20% | 25.62M | |
| -12.91% | 19.08B | |
| -46.21% | 2.65B | |
| +18.15% | 1.87B | |
| -3.12% | 1.61B | |
| +23.78% | 1.21B | |
| -10.69% | 1.02B | |
| -20.89% | 905M | |
| -18.10% | 682M | |
| -7.14% | 716M |
- Stock Market
- Equities
- ALMKT Stock
